Previous 10 | Next 10 |
Continued progress in ongoing Phase 1/2 PYNNACLE study of PC14586, a first-in-class precision oncology investigational therapy in patients with advanced solid tumors with a p53 Y220C mutation; PMV expects to provide next clinical update in 2H 2023 Enrolled first patient in combination arm of ...
PRINCETON, N.J., Feb. 28, 2023 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP; “PMV Pharma”), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David H. Mack, Ph.D., Pres...
CRANBURY, N.J., Nov. 22, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP; “PMV Pharma”), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David H. Mack, Ph.D.,...
PMV Pharmaceuticals press release ( NASDAQ: PMVP ): Q3 GAAP EPS of -$0.40 beats by $0.02 . As of Sep. 30, 2022, PMV Pharma had $258.9M in cash, cash equivalents, and marketable securities, compared to $314.1M at Dec. 31, 2021. For further details see: PM...
Enrollment continued in the Phase 1/2 PYNNACLE study of PC14586, a first-in-class precision oncology investigational therapy in patients with advanced solid tumors with a p53 Y220C mutation Phase 1b combination trial with Merck evaluating PC14586 with KEYTRUDA ® ...
CRANBURY, N.J., Nov. 04, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced the appointment of Carol Gallagher, Pharm.D., to ...
Since the mid-June lows, highly shorted names have again been outperforming. On a relative basis, the most heavily shorted stocks have been outperforming the Russell 3,000 in that time. This has resulted in the relative strength line to break out of the downtrend that has been in ...
PMV Pharmaceuticals press release ( NASDAQ: PMVP ): Q2 GAAP EPS of -$0.38 beats by $0.04 . cash equivalents, and marketable securities of $277.4m For further details see: PMV Pharmaceuticals GAAP EPS of -$0.38 beats by $0.04
Initial PC14586 Phase 1 data presented at the American Society of Clinical Oncology Annual Meeting (ASCO) demonstrated responses in patients across multiple solid tumor types with a p53 Y220C mutation Entered into a clinical collaboration with Merck to evaluate PC14586 in combin...
Cancer-focused biotech PMV Pharmaceuticals ( NASDAQ: PMVP ) announced an agreement with Merck ( MRK ) on Monday to study its lead product candidate PC14586 in combination with Merck’s ( MRK ) anti-PD-1 therapy Keytruda in advanced solid tumors. Accordingly, ...
News, Short Squeeze, Breakout and More Instantly...
PMV Pharmaceuticals Inc. Company Name:
PMVP Stock Symbol:
NASDAQ Market:
PMV Pharmaceuticals Inc. Website:
PRINCETON, N.J., May 30, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David H. Mack, Ph.D., President and Chief Executive Off...
BOSTON and PRINCETON, N.J., May 29, 2024 (GLOBE NEWSWIRE) -- Foundation Medicine, Inc. and PMV Pharmaceuticals, Inc. (NASDAQ: PMVP; “PMV Pharma”) today announced a partnership to develop Foundation Medicine’s tissue-based comprehensive genomic profiling test, FoundationOn...
2024-05-13 08:30:02 ET Craig-Hallum analyst issues BUY recommendation for PMVP on May 13, 2024 07:30AM ET. PMVP was trading at $2.04 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 3 - Buy recommendations...